Director at Foghorn Therapeutics (FHTX) receives 28,000 stock options

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. director Neil Gallagher received a grant of stock options as part of his compensation. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.08 per share. The options vest in full on the first anniversary of the grant date, as long as he continues serving on the board of directors. After this grant, he holds 28,000 stock options directly, which are scheduled to expire on June 23, 2036. This is a compensation-related award, not an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gallagher Neil

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy)	28,000	$4.08	$114K

Holdings After Transaction: Stock Options (Right to buy) — 28,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 28,000 options Exercise price: $4.08 per share Underlying shares: 28,000 shares +2 more

5 metrics

Options granted 28,000 options Stock options award to director Neil Gallagher

Exercise price $4.08 per share Strike price of granted stock options

Underlying shares 28,000 shares Common stock underlying the options

Expiration date June 23, 2036 Option expiration for this grant

Post-grant options held 28,000 options Total derivative holdings after this award

Key Terms

Stock Options (Right to buy), grant/award acquisition, exercise price, vests in full, +1 more

5 terms

Stock Options (Right to buy) financial

"security_title: Stock Options (Right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 4.0800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in full financial

"The option vests in full on the first anniversary of the grant date"

board of directors financial

"subject to the reporting person's continued service on the board of directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 04:04 PM Accepted by SEC EDGAR 06/25/2026 - 04:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gallagher Neil

(Last)

(First)

(Middle)

99 COOLIDGE AVENUE

STE 500

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to buy)	$4.08	06/24/2026		A		28,000		⁽¹⁾	06/23/2036	Common Stock	28,000	$4.08	28,000	D

Explanation of Responses:

1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Remarks:

	/s/ Michael LaCascia, Attorney-in-Fact for Neil Gallagher	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Foghorn Therapeutics (FHTX) report for Neil Gallagher?

Foghorn Therapeutics reported that director Neil Gallagher received a grant of stock options. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.08 per share as director compensation, not through an open-market trade.

How many FHTX shares can Neil Gallagher acquire through this option grant?

The option grant allows Neil Gallagher to acquire 28,000 shares of Foghorn Therapeutics common stock. These options give him the right, but not the obligation, to purchase those shares at a fixed exercise price if the options vest and are exercised.

What is the exercise price and expiration date of Neil Gallagher’s FHTX options?

Neil Gallagher’s stock options have an exercise price of $4.08 per share and are scheduled to expire on June 23, 2036. He may choose to exercise the options before that expiration date once they become fully vested.

When do Neil Gallagher’s Foghorn Therapeutics stock options vest?

The options vest in full on the first anniversary of the grant date. Vesting is conditioned on Neil Gallagher’s continued service on Foghorn Therapeutics’ board of directors through that date, aligning the award with ongoing board participation.

Was Neil Gallagher’s FHTX Form 4 transaction a market purchase or sale?

The Form 4 transaction was an option grant, not a market purchase or sale. Code “A” indicates a grant or award, meaning Neil Gallagher received stock options from Foghorn Therapeutics as compensation rather than buying or selling shares in the open market.

How many FHTX stock options does Neil Gallagher hold after this grant?

After this transaction, Neil Gallagher holds 28,000 stock options directly. These options are linked to an equal number of underlying Foghorn Therapeutics common shares and represent his current derivative position from this particular compensation award.